a building embellished with the words "National Institutes of Health" — health coverage from STAT
Mark Wilson/Newsmakers

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

After years of prodding, the National Institutes of Health has adopted a new policy requiring companies seeking licenses to sell medical products invented with government research to submit plans for ensuring greater access to patients.

Going forward, a company would not only have to submit an access plan when seeking to license the rights to sell a drug, vaccine or device, but would also have to update that plan as product development progresses. And a version of the plan would have to submitted within three months of regulatory approval that the NIH may publish or otherwise make distribute.

Advertisement

In explaining its move, which was signaled last May with a notice in the Federal Register, the agency noted in its new policy that it “relies on partners, including licensees, to turn inventions into new products and services that can directly impact people’s lives… but all too often patients across the globe may be unable to access products they need.”

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe